Abdelhamid Salim, Achermann Rita, Hollinger Alexa, Hauser Madlaina, Trutmann Maren, Gallacchi Laura, Siegemund Martin
Intensive Care Unit, Department of Acute Medicine, University Hospital Basel, Basel, Switzerland.
Department of Clinical Research, University of Basel, Basel, Switzerland.
Crit Care Med. 2024 May 1;52(5):e234-e244. doi: 10.1097/CCM.0000000000006218. Epub 2024 Feb 7.
The aim of this study was to analyze the development of albumin administration in patients admitted to the adult ICU. In addition, we assessed the impact of albumin administration on serum hemoglobin concentration.
We conducted a retrospective single-center study including all patients who were admitted to the ICU from January 2013 to December 2021 and stayed at least 24 hours.
The study was conducted in an academic hospital (University Hospital Basel, Switzerland).
A total of 20,927 admissions were included, of which 3748 received albumin at least once during their ICU stay. To analyze volume expansion, 2006 admissions met the inclusion criteria, namely at least two hemoglobin measurements within 12 hours, one albumin delivery, and experienced no bleeding, dialysis, or transfusions during this period.
None.
We examined the hemoglobin levels before and after albumin administration and compared them with a matched control group to assess the amount and duration of volume expansion.
From 2013 to 2021 the proportion of critically ill patients treated with albumin rose from 5.0% to 32.5%. An overproportioned increase in albumin use could be seen in surgical patients (4.7-47.2%) and in those receiving RBC transfusion (13.7-72.6%). In those patients receiving albumin, a significant drop in hemoglobin of around 5 g/L on average could be observed following treatment with albumin.
Hemodilution was observable for at least 12 hours after albumin administration and may have caused a decrease in hemoglobin concentration of greater than 8 g/L when isooncotic albumin solution (5%, 25 g in 500 mL) was administered. This makes albumin, especially in its isooncotic form, an ideal colloid to achieve long-lasting volume expansion. However, RBC transfusions may increase under albumin therapy, as transfusion thresholds may be undershot after albumin administration.
本研究旨在分析入住成人重症监护病房(ICU)患者白蛋白使用情况的发展。此外,我们评估了白蛋白使用对血清血红蛋白浓度的影响。
我们进行了一项回顾性单中心研究,纳入了2013年1月至2021年12月期间入住ICU且住院至少24小时的所有患者。
该研究在一家学术医院(瑞士巴塞尔大学医院)进行。
共纳入20927例入院患者,其中3748例在ICU住院期间至少接受过一次白蛋白治疗。为分析容量扩充情况,2006例入院患者符合纳入标准,即在12小时内至少进行两次血红蛋白测量、接受一次白蛋白输注,且在此期间未发生出血、透析或输血。
无。
我们检测了白蛋白输注前后的血红蛋白水平,并与匹配的对照组进行比较,以评估容量扩充的量和持续时间。
2013年至2021年,接受白蛋白治疗的重症患者比例从5.0%上升至32.5%。外科患者(从4.7%至47.2%)和接受红细胞输血的患者(从13.7%至72.6%)中白蛋白使用量有过度增加的情况。在接受白蛋白治疗的患者中,使用白蛋白治疗后平均血红蛋白水平显著下降约5g/L。
输注白蛋白后至少12小时可观察到血液稀释,当输注等容白蛋白溶液(5%,500mL中含25g)时,可能导致血红蛋白浓度下降超过8g/L。这使得白蛋白,尤其是其等容形式,成为实现持久容量扩充的理想胶体。然而,在白蛋白治疗下红细胞输血可能会增加,因为输注白蛋白后输血阈值可能未达到。